U.S. Obesity Treatment Market Size & Outlook, 2024-2030

The obesity treatment market in the United States is expected to reach a projected revenue of US$ 48,498.2 million by 2030. A compound annual growth rate of 24.2% is expected of the United States obesity treatment market from 2025 to 2030.
Revenue, 2024 (US$M)
$11,194.0
Forecast, 2030 (US$M)
$48,498.2
CAGR, 2025 - 2030
24.2%
Report Coverage
U.S.

U.S. obesity treatment market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

U.S. obesity treatment market, 2018-2030 (US$M)

U.S. obesity treatment market highlights

  • The U.S. obesity treatment market generated a revenue of USD 11,194.0 million in 2024 and is expected to reach USD 48,498.2 million by 2030.
  • The U.S. market is expected to grow at a CAGR of 24.2% from 2025 to 2030.
  • In terms of segment, glp-1 receptor agonists was the largest revenue generating drug class in 2024.
  • Other Drug Class is the most lucrative drug class segment registering the fastest growth during the forecast period.


Obesity treatment market data book summary

Market revenue in 2024USD 11,194.0 million
Market revenue in 2030USD 48,498.2 million
Growth rate24.2% (CAGR from 2025 to 2030)
Largest segmentGlp-1 receptor agonists
Fastest growing segmentOther Drug Class
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationGLP-1 Receptor Agonists, Lipase Inhibitors (Orlistat), Appetite Suppressants (Phentermine, Lorcaserin), Other Drug Class


Other key industry trends

  • In terms of revenue, U.S. accounted for 70.3% of the global obesity treatment market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In North America, U.S. obesity treatment market is projected to lead the regional market in terms of revenue in 2030.
  • U.S. is the fastest growing regional market in North America and is projected to reach USD 48,498.2 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Obesity Treatment Market Companies

Name Profile # Employees HQ Website

U.S. obesity treatment market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to obesity treatment market will help companies and investors design strategic landscapes.


Glp-1 receptor agonists was the largest segment with a revenue share of 135.64% in 2024. Horizon Databook has segmented the U.S. obesity treatment market based on glp-1 receptor agonists, lipase inhibitors (orlistat), appetite suppressants (phentermine, lorcaserin), other drug class covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to U.S. obesity treatment market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of U.S. obesity treatment market databook

  • Our clientele includes a mix of obesity treatment market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the U.S. obesity treatment market , including forecasts for subscribers. This country databook contains high-level insights into U.S. obesity treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

US Drug Class - Obesity Treatment Market size, 2024 - 2030 (US$M)

U.S. Obesity Treatment Market Outlook Share, 2024 & 2030 (US$M)

US Drug Class - Obesity Treatment Market size, 2024 - 2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more